Isomorphic Labs' chief executive, Sir Demis Hassabis, delivering his Nobel Prize lecture in 2024. Alphabet-backed start-up Isomorphic Labs has added to the lustre attached to its AI-powered drug ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Isomorphic Labs, an AI drug discovery and development company, raised $2.1 billion in a Series B funding round led by Thrive Capital. The raise was also backed by existing investors Alphabet and GV ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Demis Hassabis, CEO of Isomorphic and Google DeepMind Isomorphic, which formed as an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...

Isomorphic Labs raised $2.1 billion in its Series B funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas. The subsidiary of Google parent Alphabet ...

Advanced discussions are underway to raise more than $2B for Isomorphic Labs, an AI-driven drug discovery firm spun out of Alphabet's (GOOG) Google DeepMind, as part of a new funding round, Bloomberg ...

Isomorphic Labs Inc., an Alphabet Inc. unit using artificial intelligence to speed up drug development, is reportedly in talks to raise a new funding round. Sources told Bloomberg today that the ...

Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, is set to begin human trials of drugs designed by its Nobel Prize-winning AI technology. No one can deny the role of Google DeepMind ...